Indian Real-World Study Highlights Rising Use of Triple FDCs in T2DM

Outpatient Real-World Setting Across India: The DAPATURN Study Type 2 diabetes mellitus (T2DM) affects nearly 589 million adults globally, driving microvascular and macrovascular complications through chronic hyperglycemia, obesity, hypertension, and dyslipidemia, with India facing a particularly heavy burden due to early onset and high cardiometabolic risk . The DAPATURN study , an observational cross‑sectional analysis across 661 outpatient sites in four Indian zones (March–December 2024), enrolled 34,443 T2DM adults (mean age 54.9 ± 11.4 years; HbA1c 8.53 ± 1.56%; BMI 27.2 ± 4.9 kg/m²) receiving dapagliflozin monotherapy or fixed‑dose combinations (FDCs), capturing demographics, comorbidities, and prescribing patterns without exclusions for common real‑world factors like moderate CKD.

The dapagliflozin + sitagliptin + metformin triple FDC was most common (n = 11,657; 33.8% ),…